Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: Their roles in tumor progression and prognostication of the patient

Modern Pathology

Volumn 24, Issue 8, 2011, Pages 1146-1155

  Yamamoto, Sohei ^a   Tsuda, Hitoshi ^b   Miyai, Kosuke ^a   Takano, Masashi ^a   Tamai, Seiichi ^c   Matsubara, Osamu ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c NATIONAL DEFENSE MEDICAL COLLEGE HOSPITAL   (Japan)

Author keywords

c Met; clear cell adenocarcinoma; gene amplification; in situ hybridization; MET; ovarian cancer; prognostic factor

Indexed keywords

SCATTER FACTOR RECEPTOR;

ARTICLE; CANCER STAGING; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; OVARY ADENOCARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR GROWTH;

ADENOCARCINOMA, CLEAR CELL; DISEASE PROGRESSION; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 79961028656     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2011.70     Document Type: Article

References (38)

1. Lee KR, Tavassoli FA, Part J, et al. Surface epithelialstromal tumours. In: Tavassoli FA, Devilee P (eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. IARC Press: Lyon, 2003. pp 117-145.
2. Kaku T, Ogawa S, Kawano Y, et al. Histological classification of ovarian cancer. Med Electron Microsc 2003;36:9-17. (Pubitemid 36504385)
3. Gynecologic cancer committee, Japan society of obstetrics and gynecology. Annual report of gynecological cancer patients in Japan 2006. Acta Obstet Gynecol Jpn 2008;60:1001-1085 (in Japanese).
4. Chan JK, Teoh D, Hu JM, et al. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol 2008;109:370-376.
5. Mizuno M, Kikkawa F, Shibata K, et al. Long-term follow-up and prognostic factor analysis in clear cell adenocarcinoma of the ovary. J Surg Oncol 2006;94: 138-143. (Pubitemid 44267195)
6. O'Brien ME, Schofield JB, Tan S, et al. Clear cell epithelial ovarian cancer (mesonephroid): bad prognosis only in early stages. Gynecol Oncol 1993;49:250-254. (Pubitemid 23170001)
7. Takano M, Kikuchi Y, Yaegashi N, et al. Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer 2006;94:1369-1374. (Pubitemid 43772268)
8. Ma PC, Maulik G, Christensen J, et al. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 2003;22:309-325. (Pubitemid 36791889)
9. Peruzzi B, Bottaro DP. Targeting the c-Met signaling pathway in cancer. Clin Cancer Res 2006;12:3657-3660. (Pubitemid 44000247)
10. Birchmeier C, Birchmeier W, Gherardi E, et al. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-925. (Pubitemid 37493640)
11. Lorenzato A, Olivero M, Patanè S, et al. Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion. Cancer Res 2002;62:7025-7030. (Pubitemid 35424097)
12. Tanyi J, Tory K, Rigó Jr J, et al. Evaluation of the tyrosine kinase domain of the Met proto-oncogene in sporadic ovarian carcinomas. Pathol Oncol Res 1999; 5:187-191. (Pubitemid 29510771)
13. Schmidt L, Junker K, Nakaigawa N, et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 1999;18:2343-2350. (Pubitemid 29192711)
14. Kuniyasu H, Yasui W, Kitadai Y, et al. Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem Biophys Res Commun 1992;189:227-232. (Pubitemid 23030031)
15. Tsujimoto H, Sugihara H, Hagiwara A, et al. Amplification of growth factor receptor genes and DNA ploidy pattern in the progression of gastric cancer. Virchows Arch 1997;431:383-389. (Pubitemid 27519371)
16. Hara T, Ooi A, Kobayashi M, et al. Amplification of cmyc, K-sam, and c-met in gastric cancers: detection by fluorescence in situ hybridization. Lab Invest 1998;78:1143-1153. (Pubitemid 28440830)
17. Miller CT, Lin L, Casper AM, et al. Genomic amplification of METwith boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma. Oncogene 2006;25:409-418. (Pubitemid 43117626)
18. Zhao X, Weir BA, LaFramboise T, et al. Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res 2005;65: 5561-5570. (Pubitemid 40911156)
19. Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007; 104:20932-20937.
20. Di Renzo MF, Olivero M, Giacomini A, et al. Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res 1995;1:147-154.
21. Di Renzo MF, Narsimhan RP, Olivero M, et al. Expression of the Met/HGF receptor in normal and neoplastic human tissues. Oncogene 1991;6: 1997-2003. (Pubitemid 21924039)
22. Huntsman D, Resau JH, Klineberg E, et al. Comparison of c-met expression in ovarian epithelial tumors and normal epithelia of the female reproductive tract by quantitative laser scan microscopy. Am J Pathol 1999;155:343-348. (Pubitemid 29370384)
23. Wong AS, Roskelley CD, Pelech S, et al. Progressive changes in Met-dependent signaling in a human ovarian surface epithelial model of malignant transformation. Exp Cell Res 2004;299:248-256. (Pubitemid 39078399)
24. Ayhan A, Ertunc D, Tok EC, et al. Expression of the c-Met in advanced epithelial ovarian cancer and its prognostic significance. Int J Gynecol Cancer 2005;15:618-623. (Pubitemid 41022899)
25. Sawada K, Radjabi AR, Shinomiya N, et al. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res 2007;67: 1670-1679. (Pubitemid 46383393)
26. Zhou HY, Pon YL, Wong AST. HGF/MET signaling in ovarian cancer. Curr Mol Med 2008;8:469-480.
27. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216. (Pubitemid 30099779)
28. Nitta H, Hauss-Wegrzyniak B, Lehrkamp M, et al. Development of automated brightfield double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence in situ hybridization (FISH). Diagn Pathol 2008;3:41.
29. Pauletti G, Dandekar S, Rong H, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000;18:3651-3664.
30. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005;97:643-655. (Pubitemid 40812628)
31. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-1043. (Pubitemid 46799492)
32. Smolen GA, Sordella R, Muir B, et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci USA 2006;103: 2316-2321. (Pubitemid 43271667)
33. Beviglia L, Matsumoto K, Lin CS, et al. Expression of the c-Met/HGF receptor in human breast carcinoma: correlation with tumor progression. Int J Cancer 1997; 74:301-309. (Pubitemid 27321800)
34. Osada R, Horiuchi A, Kikuchi N, et al. Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxiainducible factor 1alpha is an independent prognostic factor in ovarian carcinoma. Hum Pathol 2007;38: 1310-1320. (Pubitemid 47247486)
35. Yasuda M, Miyazawa M, Fujita M, et al. Expression of hypoxia inducible factor-1alpha (HIF-1alpha) and glucose transporter-1 (GLUT-1) in ovarian adenocarcinomas: difference in hypoxic status depending on histological character. Oncol Rep 2008;19:111-116. (Pubitemid 351176138)
36. Yamamoto S, Tsuda H, Suzuki K, et al. An allelotype analysis indicating the presence of two distinct ovarian clear-cell carcinogenic pathways: endometriosis-associated pathway vs clear-cell adenofibroma-associated pathway. Virchows Arch 2009;455: 261-270.
37. Nam HJ, Chae S, Jang SH, et al. The PI3K-Akt mediates oncogenic Met-induced centrosome amplification and chromosome instability. Carcinogenesis 2010;31: 1531-1540.
38. Kuo KT, Mao TL, Jones S, et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol 2009;174:1597-1601.